

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1-8. (Cancelled)

9. (Currently Amended) A regime for determining whether a sample of skin or of a skin equivalent contains a papillary fibroblast population as a marker that indicates normal skin comprising the steps of:

- (a) labeling the skin or skin equivalent with at least one antibody specific for papillary fibroblasts, and wherein the at least one antibody specific for papillary fibroblasts includes ~~an anti-PG4~~ a PG4 monoclonal antibody; and
- (b) determining whether the skin or skin equivalent binds said antibody, wherein said binding indicates normal skin.

10. (Previously Presented) The regime of claim 9, wherein the labeling is present at the upper dermis at the level of the epidermis.

11. (Currently Amended) A regime for determining the presence of papillary fibroblasts in a sample comprising:

- (a) labeling said sample with at least one antibody specific for papillary fibroblasts, and wherein the at least one antibody comprises ~~an anti-PG4~~ a PG4 monoclonal antibody; and
- (b) determining presence of bound antibody as a marker for the presence of said papillary fibroblasts.

12. (Previously Presented) The regime of Claim 11, wherein the sample is a skin or skin equivalent sample.

13. (Previously Presented) The regime of Claim 12, wherein the labeling is present at the upper dermis at the level of the epidermis in the skin or skin equivalent sample.

14. (New) A regime for determining whether a sample of skin or of a skin equivalent contains a papillary fibroblast population comprising the steps of:

(a) labeling the skin or skin equivalent with at least one antibody specific for papillary fibroblasts, and wherein the at least one antibody specific for papillary fibroblasts includes a PG4 monoclonal antibody; and

(b) determining whether the skin or skin equivalent binds said antibody, wherein said binding indicates a papillary fibroblast population.

15. (New) The regime of claim 14, wherein the labeling is present at the upper dermis at the level of the epidermis.